Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  JD.com, Inc.    JD


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

JD com : Health's “Unprecedented Attention” to Drug Safety

share with twitter share with LinkedIn share with facebook
09/17/2020 | 08:25am EDT

by Hui Zhang

'Consumers attach much more importance to the reliability and safety of health products than other products,' said Enlin Jin, general manager of JD Pharmacy. 'With that in mind, JD Health pays unprecedented attention to medical safety.'

JD Health is committed to the highest standard of drug safety, making full use of a world-class team of pharmacists and doctors, cutting-edge technology, and a strong supply chain and risk management capabilities to ensure peace of mind for online patients.

During the COVID-19 outbreak earlier this year, JD Pharmacy, the pharmaceutical business branch of JD Health, not only ensured the circulation and supply of drugs across China but also offered professional medical guidance and consultation through more than 50,000 practicing physicians on its platform. Of this extensive network of medical professionals, 300 work full-time, and most have more than 10 years of clinical experience.

To ensure the utmost safety of patients, JD Pharmacy divides drugs on the platform into six different categories: A, B, C, D, E and X, in ascending order of risk. For example, for drugs belonging to category B, the platform will control the prescription dosage and will provide patients with more frequent reminders on drug use, but otherwise take a lighter hand. Drugs belonging to the highest-risk category X, such as Tyronine, are prohibited from display and sale on the platform by means of sensitive word control and manual screening.

In the past, doctors relied on their knowledge and experience to provide prescriptions, resulting in different prescription standards and low efficiency in drug review. To ensure higher consistency and accuracy, JD Pharmacy applies big data and AI to analyze drug use and past adverse reactions to offer guidance to doctors prescribing drugs.

Patients will also receive instructions and safety tips via SMS or WeChat notifications, and have the ability to chat or message with medical professionals directly in the app-just one more way in which JD Health is committed to ensuring peace of mind for online patients.



JD.com Inc. published this content on 17 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2020 11:24:07 UTC

share with twitter share with LinkedIn share with facebook
All news about JD.COM, INC.
10/30JD COM : Builds Lab in Wuhan to Provide IoV Solutions
10/30JD COM : .ID Launches AR Makeup Try-on Feature On Its app
10/29JD COM : Logistics Wins National Awards for Fight Against COVID-19
10/29JD COM : Health Launches “Family Care Project”
10/29JD COM : Applies New Services to Provide Better Shopping Experience during Singl..
10/29C2M : JD's Data to Change China's Manufacturing Industry
10/28JD COM : CEO Richard Liu's Perseverance With Integrity Earns 's Market Recogniti..
10/25JD COM : Adds New Air Cargo Route to Speed up Delivery Service
10/22GSSC SERIES : JD Launches Logistics Technology Brand, Will Deploy Over 100,000 R..
10/21JD COM : Super Boosts Development of Tea Industry
More news
Sales 2020 731 B 109 B 109 B
Net income 2020 21 996 M 3 287 M 3 287 M
Net cash 2020 86 271 M 12 892 M 12 892 M
P/E ratio 2020 37,7x
Yield 2020 -
Capitalization 851 B 127 B 127 B
EV / Sales 2020 1,05x
EV / Sales 2021 0,83x
Nbr of Employees 240 000
Free-Float 69,1%
Chart JD.COM, INC.
Duration : Period :
JD.com, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JD.COM, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 39
Average target price 594,89 CNY
Last Close Price 545,52 CNY
Spread / Highest target 28,6%
Spread / Average Target 9,05%
Spread / Lowest Target -14,3%
EPS Revisions
Qiang Dong Liu Chairman & Chief Executive Officer
Nan Li Director-Strategy & Operations
Ran Xu Chief Financial Officer, Senior VP & CFO-JD Retail
Chi Ping Lau Director
Ming Huang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JD.COM, INC.131.39%127 212
AMAZON.COM, INC.64.31%1 608 362
WAYFAIR INC.174.46%24 397
ETSY, INC.174.47%15 801
MONOTARO CO., LTD.98.43%13 483
ZOZO, INC.27.02%8 071